What SEC filings does Fennec Pharmaceuticals Inc. submit to the SEC?

Fennec Pharmaceuticals Inc. (FENC) submits several types of SEC filings including Form 4 (insider transactions), Form 144 (proposed insider sales), 8-K reports (material events such as earnings releases, acquisitions, leadership changes), and periodic reports — the 10-Q (quarterly) and 10-K (annual). All filings are publicly available through SEC EDGAR.

What does a Form 4 filing tell me about FENC?

A Form 4 for FENC discloses a transaction by a company insider — typically a director, officer, or 10%+ shareholder. It shows the source-reported date, number of shares, price, and updated ownership. These facts do not establish motive or predict future returns.

How do I interpret an 8-K filing from Fennec Pharmaceuticals Inc.?

An 8-K signals a material event requiring prompt disclosure. Common triggers include earnings pre-announcements, acquisitions, leadership appointments or departures, credit changes, or regulatory actions. Read the item codes inside the filing to understand exactly what was disclosed before drawing conclusions.

What is the difference between a 10-K and 10-Q for FENC?

The 10-K is Fennec Pharmaceuticals Inc.'s annual report with fully audited financial statements, comprehensive MD&A, and complete risk factor disclosures — filed 60–90 days after fiscal year-end. The 10-Q is a lighter quarterly report with unaudited financials filed for the first three quarters. Together they provide a continuous financial picture of the company.

Where can I see all FENC SEC filings directly on EDGAR?

You can view all historical Fennec Pharmaceuticals Inc. filings on the SEC EDGAR company page for FENC. Each filing card on this page links directly to the original SEC document.

How often does Fennec Pharmaceuticals Inc. file with the SEC?

Fennec Pharmaceuticals Inc. files one 10-K per year and up to three 10-Qs per year. Form 4 insider transactions must be reported within two business days of each trade, so the frequency depends on how often insiders are buying or selling FENC shares. 8-K filings occur whenever a material event happens — which can be several times per quarter for an active company.

FENC SEC Filing News — Fennec Pharmaceuticals Inc.

Latest SEC filings for Fennec Pharmaceuticals Inc. (FENC) explained in plain English. Covers insider buying and selling (Form 4), proposed insider sales (Form 144), material company events (8-K), and quarterly & annual reports (10-Q / 10-K). StrongBuyAnalytics provides navigation and brief excerpts or summaries; original filings remain at the SEC/source links and were authored by their filers, not StrongBuyAnalytics. Filing dates shown are source dates. Coverage and detection can be delayed or incomplete because of SEC availability, amendments, parsing, caching, or outages. Latest source filing date shown: 2026-10-01.

Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of cisplatin-induced ototoxicity pediatric patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. Fennec Pharmaceuticals Inc. has collaboration with Tampa General Hospital Foundation, Inc. for evaluation of clinical utility of sodium…

Sector: Healthcare Industry: Biotechnology Market Cap: $361.5M CIK: 1211583

Total Filings

Bullish Classifications

Bearish Classifications

Insider Transactions

Material Events (8-K)

Periodic Reports

Rule-based classifications for FENC currently lean bearish. Of the 12 filing records displayed, 3 carry bearish classifications (such as insider sales or negative 8-K disclosures) versus 0 bullish. This does not necessarily signal fundamental deterioration — insiders sell for many reasons — but it is worth monitoring alongside the company's core financial metrics.

FENC Filing Activity Snapshot 2026-08-31 — 2026-10-01

Insider Transactions (Form 4)

0 buys vs 3 sells

Net insider selling in this period — insiders sell for many reasons beyond conviction.

Largest Form 144 Filing

$160.1K

MARCO BRUGHERA · 2026-09-15

15,545 shares · Form 144

Form 144 Notices

Proposed insider sales filed — Form 144 is a notice of intent, not a confirmed transaction. Actual sales are confirmed via Form 4.

Insider Transactions 9 · Forms 3, 4 and 5

A Form 4 is filed within two business days of a company insider — an officer, a director, or a holder of more than ten percent of the stock — changing their position in the shares. All 9 filings in this group are Form 4s for Fennec Pharmaceuticals Inc.

The difficulty with reading these filings as a group is that a single form type covers transactions that mean entirely different things. An executive spending their own money to buy stock and an executive having shares withheld to pay tax on a vesting grant both appear as a Form 4. Every filing below is therefore tagged with the nature of the underlying transaction, taken from the transaction code reported on the form itself.

Across the 9 insider filings shown, the breakdown is 6 compensation award and 3 open-market sale. 3 of them involved a discretionary open-market trade; the rest are compensation and administrative mechanics.

What each transaction type means

Compensation award ×6: Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.
Open-market sale ×3: The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Form 4 Compensation award Tax / Compensation Filing 2026-10-01

FENC insider Form 4 filed for equity award, exercise, or tax withholding

Sayad Pierre Sargis (Chief Medical Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	168	—	—

Filing: Form 4 (Insider Transaction) Insider: Sayad Pierre Sargis (Chief Medical Officer) Shares: 168

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-10-01

FENC insider Form 4 filed for equity award, exercise, or tax withholding

Evans Terry L (Chief Commercial Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	168	—	—

Filing: Form 4 (Insider Transaction) Insider: Evans Terry L (Chief Commercial Officer) Shares: 168

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-10-01

FENC insider Form 4 filed for equity award, exercise, or tax withholding

Hackman Jeffrey S. (Director, Chief Executive Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	1,159	—	—

Filing: Form 4 (Insider Transaction) Insider: Hackman Jeffrey S. (Director, Chief Executive Officer) Shares: 1,159

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-10-01

FENC insider Form 4 filed for equity award, exercise, or tax withholding

Cioffi Christiana Marie (Chief Strategy Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	156	—	—

Filing: Form 4 (Insider Transaction) Insider: Cioffi Christiana Marie (Chief Strategy Officer) Shares: 156

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-10-01

FENC insider Form 4 filed for equity award, exercise, or tax withholding

Andrade Robert (CHIEF FINANCIAL OFFICER) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	1,703	—	—

Filing: Form 4 (Insider Transaction) Insider: Andrade Robert (CHIEF FINANCIAL OFFICER) Shares: 1,703

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-09-16

FENC insider Brughera Marco Maria (Director) sold 15,545 shares (~$160.0K)

Brughera Marco Maria, listed as Director at FENNEC PHARMACEUTICALS INC., reported an open-market sale of 15,545 FENC shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`M`	Option exercise	15,545	$2.11	$32.8K
`S`	Open-market sale	15,545	$10.29	$160.0K
`M`	Option exercise derivative · Stock Option	15,545	—	—

Filing: Form 4 (Insider Transaction) Insider: Brughera Marco Maria (Director) Shares: 15,545 Est. Value: $160.0K

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-09-01

FENC insider Raykov Rosty (Insider) sold 10,000 shares (~$121.1K)

Raykov Rosty, listed as Insider at FENNEC PHARMACEUTICALS INC., reported an open-market sale of 10,000 FENC shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	2,778	—	—
`S`	Open-market sale	10,000	$12.11	$121.1K

Filing: Form 4 (Insider Transaction) Insider: Raykov Rosty (Insider) Shares: 10,000 Est. Value: $121.1K

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-08-31

FENC insider Sayad Pierre Sargis (Chief Medical Officer) sold 12,000 shares (~$146.2K)

Sayad Pierre Sargis, listed as Chief Medical Officer at FENNEC PHARMACEUTICALS INC., reported an open-market sale of 12,000 FENC shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	168	—	—
`S`	Open-market sale	12,000	$12.18	$146.2K

Filing: Form 4 (Insider Transaction) Insider: Sayad Pierre Sargis (Chief Medical Officer) Shares: 12,000 Est. Value: $146.2K

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-08-31

FENC insider Form 4 filed for equity award, exercise, or tax withholding

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	168	—	—

Filing: Form 4 (Insider Transaction) Insider: Evans Terry L (Chief Commercial Officer) Shares: 168

View on SEC EDGAR → Open Filing Document →

Proposed Insider Sales 2 · Form 144

A Form 144 is a notice of intent to sell restricted or control securities. It is not a record that anything was sold. Fennec Pharmaceuticals Inc. has 2 such notices in this period.

The distinction matters because a Form 144 is frequently reported as though it were a completed insider sale. The filer may sell all of the shares covered, some of them, or none at all, and there is no obligation to update the notice either way. A sale that is actually executed by an officer or director shows up separately on a Form 4, which is the filing to check before treating a proposed sale as a real one.

Form 144 Proposed Insider Sale 2026-09-15

FENC Form 144 filed for proposed insider sale by MARCO BRUGHERA (15,545 shares) ~$160.1K

MARCO BRUGHERA filed a Form 144 with the SEC indicating intent to sell FENC (FENNEC PHARMACEUTICALS INC.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: MARCO BRUGHERA Shares: 15,545 Est. Value: $160.1K

View on SEC EDGAR → Open Filing Document →

Form 144 Proposed Insider Sale 2026-09-01

FENC Form 144 filed for proposed insider sale by ROSTISLAV RAYKOV (10,000 shares) ~$121.2K

ROSTISLAV RAYKOV filed a Form 144 with the SEC indicating intent to sell FENC (FENNEC PHARMACEUTICALS INC.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: ROSTISLAV RAYKOV Shares: 10,000 Est. Value: $121.2K

View on SEC EDGAR → Open Filing Document →

Material Events 1 · Form 8-K

An 8-K reports a material event in the window between scheduled reports. There is 1 in this period for Fennec Pharmaceuticals Inc. Each 8-K names the item number it is filed under, and that number is the fastest way to tell a routine disclosure from a consequential one.

Item 2.02 is an earnings release, Item 5.02 is a change of directors or officers, and Item 1.01 or 2.01 covers a material agreement or a completed acquisition. Item 7.01 and Item 8.01 are the general-purpose disclosure items and carry no fixed meaning on their own.

Form 8-K Material Company Update 2026-09-17

FENC filed 8-K — material company event

FENNEC PHARMACEUTICALS INC. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)

View on SEC EDGAR → Open Filing Document →

How we classify Fennec Pharmaceuticals Inc.'s filings

Straight from EDGAR

Each displayed record links to an original source document. StrongBuyAnalytics provides navigation and brief excerpts or summaries, not the filing itself. Parsing may omit context or contain errors, so read the original document in full.

Transaction codes, not guesswork

The nature shown on each insider filing comes from the transaction code the filer entered on the form itself — P for an open-market purchase, A for a compensation award, F for shares withheld to pay tax, M for an option exercise. Where one filing contains several codes, the transaction table lists them line by line.

Why the distinction matters

Insider activity is routinely summarised as buying or selling, which flattens together decisions that mean very different things. Shares withheld for tax on a vesting grant are an automatic administrative step; shares bought on the open market are someone committing their own money at the current price.

What this page does not tell you

A filing records what happened, not why. Form 4 does not always disclose whether a sale was executed under a pre-arranged Rule 10b5-1 plan, and no single filing is a basis for a decision on FENC. Read these alongside the fundamentals rather than in isolation.

Frequently Asked Questions — FENC SEC Filings

More Tools for FENC

FENC Full Stock Analysis FENC Live Chart Institutional Ownership Earnings Calendar Options Flow Scanner Semiconductor Demand Zone Tracker Sector Scanner Browse All Stocks

Want deeper FENC analysis?

View valuation, growth metrics, the rule-based stock-page score, demand zones, peer comparison, and more — all on the FENC stock analysis page.

FENC Full Analysis

Publisher, sources & limitations — September 15, 2026. StrongBuyAnalytics provides navigation and brief excerpts or summaries for educational use. Original filings remain at SEC EDGAR or other displayed source links; StrongBuyAnalytics does not author them. Filing dates are source dates, not publication dates for this page. Coverage can be delayed, incomplete, amended, or unavailable because of SEC/source availability, parsing, caching, or outages. Verify every material statement in the original filing.

Data Sources · Methodology · AI Disclosure · Corrections Policy · Disclaimer